血友病基因治疗安全性、疗效与持久性的全球注册研究核心数据集
国际血栓与止血学会科学标准化委员会联合世界血友病联盟等机构,设计了一项前瞻性、观察性、纵向注册研究(GTR),旨在收集所有接受基因治疗的血友病患者长期安全性和疗效数据。该注册研究在多利益相关方指导委员会指导下,参照欧洲药品管理局和美国食品药品监督管理局的指南,制定了涵盖人口学、载体输注、安全性、疗效、生活质量和疾病负担的核心数据集。
要点
- GTR为前瞻性、观察性、纵向注册研究,目标纳入全球100%接受基因治疗的血友病患者。
- 核心数据集涵盖人口学、载体输注详情、安全性、疗效、生活质量和疾病负担。
- 注册研究旨在记录长期安全性和疗效,并识别小人群中的罕见不良事件。
核心结论
- GTR是一项全球性努力,确保记录和分析基因治疗后的长期安全性和疗效结局,并识别小患者群体中的罕见不良事件。
研究设计与样本
- GTR为前瞻性、观察性、纵向注册研究,由多利益相关方GTR指导委员会指导制定,成员包括医疗专业人员、患者倡导者、行业代表和监管机构联络人。
- 所有通过临床试验或商业产品接受基因治疗的血友病患者将通过其血友病治疗中心受邀入组,目标纳入全球100%符合条件的基因治疗后患者。
主要发现
- 核心数据集包括人口学信息、载体输注详情、安全性、疗效、生活质量和疾病负担。
关键数值与推荐
- 核心数据集经迭代过程制定,遵循欧洲药品管理局(EMA)和美国食品药品监督管理局(FDA)的指导。
临床怎么用
- 血友病治疗中心应邀请所有接受基因治疗的患者入组GTR,以收集长期安全性和疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gene therapy for people with hemophilia (PWH) will soon become available outside current clinical trials. The World Federation of Hemophilia (WFH), in collaboration with International Society of Thrombosis and Hemostasis Scientific and Standardization Committee (ISTH SSC), the European Haemophilia Consortium (EHC), the US National Hemophilia Foundation (NHF), the American Thrombosis and Hemostasis Network (ATHN), industry gene therapy development partners and Regulatory liaisons have developed the Gene Therapy Registry (GTR), designed to collect long-term data on all PWH who receive hemophilia gene therapy. OBJECTIVE: The objectives of the GTR are to record the long-term safety and efficacy data post gene therapy infusion and to assess the changes in quality of life and burden of disease post-gene-therapy infusion. METHODS: The GTR is a prospective, observational, and longitudinal registry developed under the guidance of a multi-stakeholder GTR Steering Committee (GTR SC), composed of health care professionals, patient advocates, industry representatives, and regulatory agency liaisons. All PWH who receive gene therapy by clinical trial or commercial product will be invited to enrol in the registry through their hemophilia treatment centers (HTCs). The registry aims to recruit 100% of eligible post gene therapy PWH globally. Through an iterative process, and following the guidance of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), the GTR SC has developed a core set of data to be collected on all patients post gene therapy. RESULTS: The core data set includes demographic information, vector infusion details, safety, efficacy, quality of life and burden of disease. CONCLUSIONS: The GTR is a global effort to ensure that long term safety and efficacy outcomes are recorded and analysed and rare adverse events, in a small patient population, are identified. Many unknowns on the long-term safety and efficacy of gene therapy for hemophilia may also be addressed.
引用
- Konkle B, Pierce G, Coffin D, et al. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. J Thromb Haemost. 2020. PMID: 33463024. doi:10.1111/jth.15023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。